top of page
Surgeon at Work

About Us

At VerAvanti, we aim to transform intravascular imaging through precision and innovation in patient care.

Our Mission

VerAvanti was founded to address a fundamental limitation in endoscopic imaging. Many of today’s devices were designed decades ago, relying on side-view visualization and reusable systems that can limit workflow efficiency and introduce operational challenges in modern clinical environments.

In collaboration with the University of Washington, VerAvanti developed the patented Scanning Fiber Endoscope (SFE), a new approach to endoscopic imaging designed to deliver high-quality visualization through ultra-small, single-use devices.

Our focus is to enable physicians to see more clearly, work more efficiently, and make better-informed decisions during minimally invasive procedures. By combining precision engineering with a commitment to patient safety and clinical practicality, VerAvanti is building imaging technologies designed for the needs of modern healthcare.

VerAvanti is currently pursuing 510(k) clearance by the U.S. Food and Drug Administration (FDA) and preparing to expand production and introduce our diagnostic solutions worldwide. Committed to ongoing innovation, we aim to improve healthcare standards by making procedures safer, faster, and more effective for both patients and providers.

The Timeline

LongGradient.webp

1

Foundational Research and Collaboration

Laying the groundwork for groundbreaking technology.

Initial research began in collaboration with the University of Washington, forming the basis for our fiber-optic endoscopy innovations.

LongGradient.webp

2

Prototype Testing and Validation

Ensuring safety and effectiveness through testing.

Early prototypes underwent rigorous lab and clinical testing, validating our imaging excellence.

LongGradient.webp

3

Securing 50+ Patents

Protecting our technology through comprehensive patents.

We secured over 50 patents in the U.S.A, reinforcing VerAvanti’s commitment to advancing exclusive, protected innovations.

LongGradient.webp

5

Final Production Model Established

Refining the design for scalability and precision.

The production model is under finalization, with in-house manufacturing processes set up to maintain quality and precision at scale.

LongGradient.webp

6

FDA Approval and Market Launch

Bringing VerAvanti’s innovations to healthcare providers.

With FDA approval anticipated by Q1 2026, VerAvanti is poised to launch its technology globally, redefining standards in diagnostics and treatment.

Leadership

VerAvanti_Top+Ortho(Gray+Background).jpg

Gerald McMorrow

Founder and CEO

With a proven track record for spotting and commercializing scanning and imaging technology that can make a difference in the lives of physicians worldwide, serial entrepreneur Gerald McMorrow is launching VerAvanti. Previously, McMorrow founded and led Verathon Inc., to soaring heights as Chief Executive Officer and Chairman, responsible for guiding the company’s transformation from start-up to a major international medical device corporation, before steering its eventual sale to Roper Industries. A recognized industry powerhouse, McMorrow was named Ernst & Young Entrepreneur of The Year (2006, Pacific Northwest, Health Services category) and leveraged his early engineering experience and career into the high reaches of corporate management. McMorrow worked his way through school with the aid of the G.I. Bill and has Bachelor's and Master's degrees cum laude in Electrical Engineering from the University of Washington, Seattle.
VerAvanti_Top+Ortho(Gray+Background).jpg

Luis Savastano

Chief Medical Officer

Dr. Luis Savastano is a surgeon-scientist, inventor, and serial founder dedicated to solving unmet clinical needs through translational research and the development of breakthrough medical technologies. A hybrid cerebrovascular neurosurgeon, he specializes in both microsurgical and endovascular treatment of ischemic and hemorrhagic stroke. ​ He currently serves at the University of California, San Francisco (UCSF) as Co-Chief of NeuroEndovascular Surgery, Medical Director of Cerebrovascular Neurosurgery, Program Director of the CAST-approved Cerebrovascular Fellowship, and Principal Investigator of the Translational Neurosurgery and Technology Lab (TNTLab). In these roles, Dr. Savastano leads a multidisciplinary team working at the intersection of clinical care, innovation, and device development. As Chief Medical Officer at VerAvanti, Dr. Savastano plays a key role in shaping the company’s clinical research and validation strategy. He leads efforts to advance the SFE angioscopy platform through investigator-led studies and strategic collaborations with early access partners. Through regular research meetings and case-based discussions, he works closely with academic institutions and practicing clinicians to refine the technology and accelerate its path to clinical adoption. Dr. Savastano has conducted pioneering research on VerAvanti’s SFE platform and was among the earliest to explore its use in the evaluation of carotid artery disease and stroke, demonstrating its potential to provide real-time, high-resolution intravascular visualization. His work underscores a strong commitment to translating innovation into meaningful clinical tools that improve outcomes and reshape standards of care.
VerAvanti_Top+Ortho(Gray+Background).jpg

Eric Seibel

Chief Science Officer

Research Professor of Mechanical Engineering at the University of Washington and the Director of the Human Photonics Laboratory. Eric invented the scanning fiber endoscope (SaFE) and many of its current application.
VerAvanti_Top+Ortho(Gray+Background).jpg

Juan Vegarra

Chief Revenue Officer

Mr. Vegarra has more than 30 years of experience in global business development, where he has helped organizations scale to new levels of growth and innovation. He is a visionary and passionate leader with a proven track record of executing successful sales and marketing campaigns, developing strategic partnerships, and raising capital across diverse and competitive industries. He is a serial entrepreneur who has founded, grown, and exited several ventures, raising over $75M from global institutional investors and signing over $15M in joint-venture deals.
VerAvanti_Top+Ortho(Gray+Background).jpg

David Goesling

Chief Financial Officer

Senior financial executive with extensive startup and growth-phase experience in private and public companies; skilled in raising capital and enhancing business models to drive financial results.
VerAvanti_Top+Ortho(Gray+Background).jpg

Jason Capodanno

Chief Operating Officer

Jason Capodanno is the Managing Director of Avanti with a degree in BioEngineering from the University of California at San Diego. His background in class II and III medical devices started in 1998 with Gerald McMorrow at Diagnostic Ultrasound (later Verathon) as a Manufacturing Engineer on the very successful BVI3000 Product. He then spent 6 years as a Microfluidics Design Engineer currently holding 16 patents in that field. Next he spent a decade with Philips Medical as a Design Engineer, Procurement Engineer and Supplychain/Operations. The various disciplines of Jason’s experience and leadership fits Avanti’s needs well in building a team to take a low volume/high cost product and transforming it into a high volume/low cost one.

Clinical Advisors

VerAvanti_Top+Ortho(Gray+Background).jpg

Patrick McVeigh, MD

MD

Dr. McVeigh is with the Division of Vascular Surgery at the University of Toronto. His PhD in Medical Biophysics produced the 1st in-vivo studies of intravascular imaging using the SFE.
VerAvanti_Top+Ortho(Gray+Background).jpg

Mark Reisman

Clinical Professor of Medicine

Mark Reisman is a Clinical Professor of Medicine at the University of Washington. He is also President of the Board of Directors of the Seattle Science Foundation and the Director of several cardiology programs throughout the country. Dr. Reisman has been the site Principal Investigator on more than 50 clinical trials and remains an active investigator on a multitude of trials with a focus on structural heart disease and coronary artery disease. As Director of Cardiovascular Emerging Therapies, he has a research interest in emerging technologies for the treatment of heart disease.
VerAvanti_Top+Ortho(Gray+Background).jpg

William Lombardi

Associate Clinical Professor of Medicine

Dr. Lombardi is an associate clinical professor of medicine in the Division of Cardiology, and the director for Complex Coronary Artery Disease Therapies in the UW Medicine Regional Heart Center. He is an expert in cardiac catheterization and interventional cardiology.
VerAvanti_Top+Ortho(Gray+Background).jpg

John Petersen

Director of Cardiovascular Research

John L. Petersen is Director of Cardiovascular Research at Swedish Heart & Vascular Institute and specializes in Interventional Cardiology. He attended the University of Washington School of Medicine, and completed his residency at Duke University Medical Center. Dr. Petersen is not only a renowned Cardiologist at Swedish, he also spends his time working closely with Fellows and new research on the University of Washington campus, and is a member of the American College of Cardiology, Society for Cardiovascular Angiography and Interventions and American Heart Association.

Board Members

VerAvanti_Top+Ortho(Gray+Background).jpg

Gerald McMorrow

Chairman of the Board

With a proven track record for spotting and commercializing scanning and imaging technology that can make a difference in the lives of physicians worldwide, serial entrepreneur Gerald McMorrow is launching VerAvanti. Previously, McMorrow founded and led Verathon Inc., to soaring heights as Chief Executive Officer and Chairman, responsible for guiding the company’s transformation from start-up to a major international medical device corporation, before steering its eventual sale to Roper Industries. A recognized industry powerhouse, McMorrow was named Ernst & Young Entrepreneur of The Year (2006, Pacific Northwest, Health Services category) and leveraged his early engineering experience and career into the high reaches of corporate management. McMorrow worked his way through school with the aid of the G.I. Bill and has Bachelor's and Master's degrees cum laude in Electrical Engineering from the University of Washington, Seattle.
VerAvanti_Top+Ortho(Gray+Background).jpg

Fred Moll

M.D., Founder and CEO of Auris Health

Dr. Moll is a distinguished and prolific medical device entrepreneur. He is the founder of Auris Health, which was acquired by Johnson & Johnson for $3.4 billion in 2019. Prior to Auris, he co-founded Intuitive Surgical (ISRG), now a publicly traded company with a market cap exceeding $100 billion and the global leader in robotic-assisted surgery. He also founded Hansen Medical and Restoration Robotics, and earlier served as founder and medical director of Origin Medsystems, acquired by Eli Lilly, and Endotherapeutics, acquired by United States Surgical.
VerAvanti_Top+Ortho(Gray+Background).jpg

David C. Auth

Ph.D, Affiliate Professor of Bioengineering

Dr. Auth is a renowned scientist, inventor, and serial medical device entrepreneur. He is the founder of Heart Technology, which pioneered rotational atherectomy and was acquired by Boston Scientific for over $600 million. He currently serves on several medical technology company boards and has been an Affiliate Professor of Bioengineering at the University of Washington since 1985.
VerAvanti_Top+Ortho(Gray+Background).jpg

Michael Moyer

Board Member

Mike Moyer is a corporate finance and securities attorney with almost three decades of experience serving emerging companies and the venture funds and family offices that invest in them. He is a partner at the firm of BakerHostetler where he leads the firm’s national Emerging Companies & Venture Capital group and its Seattle Business Group.  He handles public and private securities offerings, mergers and acquisitions and the formation of strategic alliances and joint ventures.
bottom of page